Phenibut is a synthetic compound related to the neurotransmitter GABA. It is sold online and in some retail stores as a nootropic or relaxation supplement, usually in powder or capsule form. It is not an approved by FDA drug, and the Food and Drug Administration does not treat it as a lawful dietary ingredient. This article explains how standard workplace and clinical drug test panels handle phenibut, what a laboratory can and cannot detect, and why employers should route anything unusual back through a medical review officer rather than guessing.
This article does not describe any way to evade or interfere with a drug test. It describes how screening and confirmation testing work from the employer and laboratory side.
What phenibut is and why it is not a regulated drug or supplement
Phenibut (beta phenyl gamma aminobutyric acid) was developed in another country decades ago and is used there as a prescription anxiolytic. In the United States it has never gone through FDA new drug approval, and it does not meet the legal definition of a dietary ingredient that can be marketed without new ingredient notification. Manufacturers who want to add a genuinely new dietary ingredient to a supplement are required to notify the FDA with safety information before marketing it; the agency does not pre-approve dietary ingredients, it reviews notifications and can act against products it considers adulterated or misbranded once they reach the market, as the FDA's New Dietary Ingredient notification process page explains. Phenibut products sold as "supplements" generally have not gone through that process in a way the agency has accepted, which is part of why compliance teams should not describe phenibut as approved by FDA, FDA cleared, or a verified dietary ingredient in any policy document or customer communication.
Phenibut is also not listed as a controlled substance under the federal Controlled Substances Act schedules maintained by the Drug Enforcement Administration. The current Schedule I listing of substances, reproduced at 21 CFR 1308.11 through Cornell Law School's Legal Information Institute, does not include phenibut. That means, at the federal level, simple possession of phenibut is not treated the way possession of a scheduled drug is. State law is a different question, covered below.
Immunoassay screening versus confirmation testing
Standard workplace and clinical drug tests, whether a cup, a dip card, or an oral fluid device, rely on immunoassay chemistry. Each test strip or well is built around antibodies that bind to a specific drug class, such as opiates, amphetamines, benzodiazepines, or THC metabolites. The antibody only reacts to molecules that are structurally similar enough to the target drug class to trigger a positive or negative line. Phenibut is a GABA analog. It is not chemically related to opioids, amphetamines, benzodiazepines, cocaine metabolites, PCP, or THC, the drug classes found on standard 5, 10, and 12 panel immunoassay cups and cards. There is no published, peer reviewed evidence that phenibut cross reacts with any of those standard immunoassay panels. Employers and donors should treat that absence of evidence as exactly what it is: no credible cross reactivity has been documented, not a promise about every product or every lab's exact reagent lot.
Because phenibut is not one of the analytes a standard panel is built to detect, a routine immunoassay screen will not identify phenibut use on its own. Detecting phenibut specifically requires a laboratory to run a targeted method, typically liquid chromatography tandem mass spectrometry (LC/MS or LC/MS/MS), looking for phenibut by name as part of an expanded or custom testing menu. This is the same confirmation chemistry labs already use to confirm a presumptive positive from a screening immunoassay; the only difference is that phenibut has to be specifically requested as part of a broader panel or forensic toxicology workup rather than assumed to show up on a generic cup.
| Test type | What it detects | Will it catch phenibut |
|---|---|---|
| Standard immunoassay cup or dip card (5 to 12 panel) | Opiates, amphetamines, THC, cocaine metabolites, benzodiazepines, PCP, barbiturates, and similar antibody targeted classes | No, phenibut is not one of the target classes and there is no documented cross reactivity |
| Oral fluid immunoassay | Same general drug classes as urine immunoassay, adapted for saliva chemistry | No, same reasoning as above |
| Expanded laboratory panel with GC/MS or LC/MS confirmation | Whatever analytes the ordering party specifies, including non standard compounds | Only if phenibut is specifically named as a target analyte |
| Clinical or forensic toxicology workup | Broad or targeted compound screening depending on the clinical question | Possible, this is the setting where phenibut is most likely to be specifically tested for, such as in an emergency department evaluating withdrawal |
Why a false positive or false negative question still goes to the MRO
Any unusual result, or any employee disclosure of phenibut use, should go through the same medical review officer process used for prescription medications. An MRO is a licensed physician trained to interpret laboratory results, contact the donor confidentially, and review medical and prescription documentation before a result is reported to an employer as positive, negative, or refusal to test. If an employer has reason to believe an employee has used phenibut, whether from a disclosure, a workplace incident, or a non-standard clinical test ordered after an incident, that information belongs with the MRO and the company's existing drug free workplace policy, not with a supervisor trying to interpret a cup result. Employers should never attempt to diagnose dependence, withdrawal, or impairment themselves; that is a medical determination.
Dependence and withdrawal risk for safety sensitive roles
Phenibut acts on GABA-B receptors in the central nervous system, and case literature has described tolerance, dependence, and a withdrawal syndrome with regular higher dose use, including anxiety, insomnia, and in some reported cases more severe autonomic symptoms. The National Institute on Drug Abuse, the NIH institute that funds and publishes research on substance use and dependence, is a useful starting point for employers and safety managers who want current, government sourced background on how dependence and withdrawal are studied generally, available at nida.nih.gov. For safety sensitive positions, an employer's concern is less about whether a specific panel flags phenibut and more about whether an employee shows signs of impairment or withdrawal on the job. That is a fitness for duty and medical evaluation question, handled through occupational health and the MRO process, not something a screening cup is designed to answer. Consumers with questions about a specific supplement ingredient can also check the National Library of Medicine's consumer drug and supplement information service, MedlinePlus Drugs, Herbs and Supplements, though it should not replace advice from a treating clinician.
State law varies and changes
Phenibut's legal status outside the federal Controlled Substances Act is set state by state, and it changes over time as state boards of pharmacy and legislatures add newly identified synthetic substances to their own controlled substance schedules. States generally do this either through statute or through an administrative rulemaking process run by the state board of pharmacy; Virginia's regulation on placing chemicals into its own Schedule I, for example, shows how one state's board handles exactly this kind of addition, at 18VAC110-20-322. Because these lists are updated on an ongoing basis and differ by state, employers should not assume phenibut is legal, illegal, or scheduled in their state based on a national overview. Confirm current status with your own state board of pharmacy or legal counsel before writing phenibut specifically into a drug free workplace policy.
What this means for an employer drug testing program
For most employers, the practical takeaway is straightforward. Standard panel cups and cards, whether urine or oral fluid, were not built to detect phenibut and there is no credible evidence they cross react with it. If a specific concern about phenibut use comes up, whether from a workplace incident, an employee disclosure, or a referral from occupational health, the path is a targeted laboratory test through a certified lab, not a different consumer cup. Program design questions, including whether to add expanded or custom analyte testing, are best worked out with your laboratory and your MRO so the policy, the panel, and the documentation all match.
Frequently asked questions
Does a standard drug test cup detect phenibut?
No. Standard immunoassay cups and dip cards are built around antibody reactions to specific drug classes such as opiates, amphetamines, benzodiazepines, and THC metabolites. Phenibut is not chemically part of any of those classes, and there is no published evidence of cross reactivity on standard panels.
Can a laboratory test for phenibut specifically?
Yes. A laboratory can run a targeted LC/MS or LC/MS/MS method that looks for phenibut by name, but it has to be ordered as part of an expanded panel or a forensic or clinical toxicology workup. It is not part of a routine immunoassay screen.
Is phenibut approved by FDA or a legal dietary supplement?
No. Phenibut has not gone through FDA new drug approval, and products marketed as phenibut supplements generally have not completed the agency's new dietary ingredient process in a way the FDA has accepted. Employers and sellers should never describe it as approved by FDA.
Is phenibut a federally controlled substance?
No. It does not appear on the DEA's federal Controlled Substances Act schedules. Some states have separately moved to schedule it or restrict its sale under their own laws, and those rules vary and change, so check current state law directly.
What should an employer do if an employee discloses phenibut use?
Route it through the medical review officer and your existing drug free workplace policy, the same way you would handle a prescription medication disclosure. Do not attempt to interpret dependence, withdrawal, or fitness for duty without a qualified medical evaluation.
Where can an employer buy standard drug test cups and panels?
American Screening Corporation supplies drug test cups, dip cards, and oral fluid tests to employers and testing programs; see the drug test cup collection for standard panel options. For related topics, see Do Bath Salts Show Up on a Drug Test? and Does Kava Show Up on a Drug Test? for other unregulated supplement and novel substance questions.
This article is general information, not legal or medical advice. Consult qualified counsel or a medical review officer for decisions about a specific workplace policy or test result.
